Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor

This study aimed to evaluate a modified EPclin test (mEPclin), a combination of EndoPredict (EP) score, post-neoadjuvant pathologic tumor size and nodal status, for predicting the risk of distance recurrence after neoadjuvant chemotherapy (NACT) in patients with residual estrogen receptor (ER)-posit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2018-07, Vol.24 (14), p.3358-3365
Hauptverfasser:	Loibl, Sibylle, Weber, Karsten, Huober, Jens, Krappmann, Kristin, Marmé, Frederik, Schem, Christian, Engels, Knut, Pfitzner, Berit Maria, Kümmel, Sherko, Furlanetto, Jenny, Hartmann, Arndt, Darb-Esfahani, Silvia, Müller, Volkmar, Staebler, Annette, von Minckwitz, Gunter, Kronenwett, Ralf, Denkert, Carsten
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - etiology Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer Chemotherapy Chemotherapy, Adjuvant Clinical Trials, Phase III as Topic Combined Modality Therapy Confidence intervals ErbB-2 protein Estrogen receptors Estrogens Experimental design Female Gene expression Gene Expression Profiling Health risks Humans Kaplan-Meier Estimate Medical prognosis Middle Aged Multivariate analysis Neoadjuvant Therapy Neoplasm Grading Neoplasm Staging Paraffin Paraffins Patients Prognosis Risk Assessment Survival Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!